Investors

Roche’s Virtual Oncology/SABCS Investor Event

Thursday, 11 December at 16:30 CET

A gloved hand in a lab coat holds a small, clear vial against a blurred background of lab equipment, conveying a scientific and clinical setting.

Roche’s 3rd Quarter Sales 2025 Presentation

Roche has published its Third Quarter Sales for 2025 prior to the opening of the Swiss Stock Exchange on Thursday, 23rd October 2025.

Please click here to watch the replay of the webinar.
Presentation download
Presentation download with appendix

A gloved hand holds a pink laboratory sample above a table with three colored containers—green, blue, yellow. The scene is precise and sterile.

24 million

patients were treated with Roche medicines in 2024

30 billion

Roche Diagnostics test were delivered to customers worldwide in 2024

+1%

Core investments in research and development in 2024: CHF 13.2 billion

Product Development Pipeline

Why Invest

Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.

Dr Thomas Schinecker

CEO Roche Group

Investor updates

View all updates

View ad-hoc announcements

Upcoming Investor events

View all events

Roche’s Virtual Oncology/SABCS Investor Event Investors

Thursday, 11 December at 16:30 CET | Basel, Switzerland

Add to calendar

J.P. Morgan 2026 Healthcare ConferenceInvestors

January 12, 2026 at 10:00 PST | San Francisco, US

Add to calendar

Octavian Seminar 2026Investors

January 15, 2026 at 10:00 CET | Davos, CH

Add to calendar

Roche Full Year Results 2025 (virtual event)Investors

January 29, 2026 at 13:30 CET | Basel, Switzerland

Add to calendar

2026 Annual General Meeting (tentative)Investors

March 10, 2026 at 10:30 CET | Basel, Switzerland

Add to calendar

Roche 1st Quarter Sales 2026 (virtual event)Investors

April 23, 2026 at 14:00 CEST | Basel, Switzerland

Add to calendar

Latest reports

Smiling scientist in a lab coat and safety glasses holds a pipette in a modern laboratory. The setting conveys focus and innovation.

Half-year report 2025Investors

Annual report 2024Investors

Finance Information Tool

Reporting

Download center

Share and Bond information

US investors

ESG Index

Investor relations team contacts

Do you need to get in touch with us? Reach out to our investor relations team with your enquiries.

View investor contact detail

Discover More

Roche Diagnostics news

Follow the most recent updates from our Diagnostics business

Genentech

Genentech has been delivering on the promise of biotechnology for over 35 years.

Sustainability at RocheAbout Roche

At Roche, our ambition lies not only in transforming healthcare, but also in our contributions to environmental protection, supply chain sustainability, social commitment and philanthropy.

Positions, policies & downloadsAbout Roche

Download our policies, guidelines, positions and other documents.

Frequently Asked QuestionsInvestors

We answer the Roche investors-related most frequently asked questions

PartneringInnovation

At Roche Partnering, we are passionate about science: yours and ours. Through partnerships, we hope that together we can build a better future with medicines that make a real difference to patients.